189 related articles for article (PubMed ID: 21869839)
1. (+)α-Tocopheryl succinate inhibits the mitochondrial respiratory chain complex I and is as effective as arsenic trioxide or ATRA against acute promyelocytic leukemia in vivo.
dos Santos GA; Abreu e Lima RS; Pestana CR; Lima AS; Scheucher PS; Thomé CH; Gimenes-Teixeira HL; Santana-Lemos BA; Lucena-Araujo AR; Rodrigues FP; Nasr R; Uyemura SA; Falcão RP; de Thé H; Pandolfi PP; Curti C; Rego EM
Leukemia; 2012 Mar; 26(3):451-60. PubMed ID: 21869839
[TBL] [Abstract][Full Text] [Related]
2. Apoptosis induction by (+)alpha-tocopheryl succinate in the absence or presence of all-trans retinoic acid and arsenic trioxide in NB4, NB4-R2 and primary APL cells.
Freitas RA; Silva dos Santos GA; Gimenes Teixeira HL; Scheucher PS; Lucena-Araujo AR; Lima AS; Abreu e Lima RS; Garcia AB; Jordão AA; Falcão RP; Vannucchi H; Rego EM
Leuk Res; 2009 Jul; 33(7):958-63. PubMed ID: 19013639
[TBL] [Abstract][Full Text] [Related]
3. Sodium selenite induces apoptosis in acute promyelocytic leukemia-derived NB4 cells by a caspase-3-dependent mechanism and a redox pathway different from that of arsenic trioxide.
Zuo L; Li J; Yang Y; Wang X; Shen T; Xu CM; Zhang ZN
Ann Hematol; 2004 Dec; 83(12):751-8. PubMed ID: 15480664
[TBL] [Abstract][Full Text] [Related]
4. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy.
Huan SY; Yang CH; Chen YC
Leuk Lymphoma; 2000 Jul; 38(3-4):283-93. PubMed ID: 10830735
[TBL] [Abstract][Full Text] [Related]
5. Tocopheramine succinate and tocopheryl succinate: mechanism of mitochondrial inhibition and superoxide radical production.
Gruber J; Staniek K; Krewenka C; Moldzio R; Patel A; Böhmdorfer S; Rosenau T; Gille L
Bioorg Med Chem; 2014 Jan; 22(2):684-91. PubMed ID: 24393721
[TBL] [Abstract][Full Text] [Related]
6. Acute promyelocytic leukemia: a paradigm for differentiation therapy.
Grimwade D; Mistry AR; Solomon E; Guidez F
Cancer Treat Res; 2010; 145():219-35. PubMed ID: 20306254
[TBL] [Abstract][Full Text] [Related]
7. Pathologic, cytogenetic and molecular assessment of acute promyelocytic leukemia patients treated with arsenic trioxide (As2O3).
Zhang T; Westervelt P; Hess JL
Mod Pathol; 2000 Sep; 13(9):954-61. PubMed ID: 11007035
[TBL] [Abstract][Full Text] [Related]
8. Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines.
Davison K; Côté S; Mader S; Miller WH
Leukemia; 2003 May; 17(5):931-40. PubMed ID: 12750708
[TBL] [Abstract][Full Text] [Related]
9. Autophagic degradation of an oncoprotein.
Bøe SO; Simonsen A
Autophagy; 2010 Oct; 6(7):964-5. PubMed ID: 20724820
[TBL] [Abstract][Full Text] [Related]
10. Hemostatic abnormalities associated with acute promyelocytic leukemia and corrective effects of all-trans-retinoic acid or arsenic trioxide treatment.
Zhao W; Wang X; Guo W; Qu B; Wang H; Shen Z; Chen Z; Wang Z
Chin Med J (Engl); 2000 Mar; 113(3):236-40. PubMed ID: 11775254
[TBL] [Abstract][Full Text] [Related]
11. What is the role of arsenic in newly diagnosed APL?
Tallman MS
Best Pract Res Clin Haematol; 2008 Dec; 21(4):659-66. PubMed ID: 19041605
[TBL] [Abstract][Full Text] [Related]
12. Arsenic trioxide in the treatment of a patient with multiply recurrent, ATRA-resistant promyelocytic leukemia: a case report.
Bergstrom SK; Gillan E; Quinn JJ; Altman AJ
J Pediatr Hematol Oncol; 1998; 20(6):545-7. PubMed ID: 9856675
[TBL] [Abstract][Full Text] [Related]
13. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
Quezada G; Kopp L; Estey E; Wells RJ
Pediatr Blood Cancer; 2008 Jul; 51(1):133-5. PubMed ID: 18293388
[TBL] [Abstract][Full Text] [Related]
14. Acute promyelocytic leukemia: new issues on pathogenesis and treatment response.
Vitoux D; Nasr R; de The H
Int J Biochem Cell Biol; 2007; 39(6):1063-70. PubMed ID: 17468032
[TBL] [Abstract][Full Text] [Related]
15. Pathways of retinoic acid- or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission.
Zhu J; Lallemand-Breitenbach V; de Thé H
Oncogene; 2001 Oct; 20(49):7257-65. PubMed ID: 11704854
[TBL] [Abstract][Full Text] [Related]
16. Arsenic trioxide-induced apoptosis in TM4 Sertoli cells: the potential involvement of p21 expression and p53 phosphorylation.
Kim YJ; Chung JY; Lee SG; Kim JY; Park JE; Kim WR; Joo BS; Han SH; Yoo KS; Yoo YH; Kim JM
Toxicology; 2011 Jul; 285(3):142-51. PubMed ID: 21565247
[TBL] [Abstract][Full Text] [Related]
17. Anthraquinones sensitize tumor cells to arsenic cytotoxicity in vitro and in vivo via reactive oxygen species-mediated dual regulation of apoptosis.
Yang J; Li H; Chen YY; Wang XJ; Shi GY; Hu QS; Kang XL; Lu Y; Tang XM; Guo QS; Yi J
Free Radic Biol Med; 2004 Dec; 37(12):2027-41. PubMed ID: 15544921
[TBL] [Abstract][Full Text] [Related]
18. JWA is required for arsenic trioxide induced apoptosis in HeLa and MCF-7 cells via reactive oxygen species and mitochondria linked signal pathway.
Zhou J; Ye J; Zhao X; Li A; Zhou J
Toxicol Appl Pharmacol; 2008 Jul; 230(1):33-40. PubMed ID: 18387645
[TBL] [Abstract][Full Text] [Related]
19. Involvement of mitochondrial aggregation in arsenic trioxide (As2O3)-induced apoptosis in human glioblastoma cells.
Haga N; Fujita N; Tsuruo T
Cancer Sci; 2005 Nov; 96(11):825-33. PubMed ID: 16271077
[TBL] [Abstract][Full Text] [Related]
20. Effect of all-trans retinoic acid and arsenic trioxide on tissue factor expression in acute promyelocytic leukemia cells.
Guo W; Wang H; Zhao W; Zhu J; Ju B; Wang X
Chin Med J (Engl); 2001 Jan; 114(1):30-4. PubMed ID: 11779431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
